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The α-synucleinopathies are a group of neurodegenerative diseases characterized by
abnormal accumulation of insoluble α-synuclein in neurons and glial cells, comprising
Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy
(MSA). Although varying in prevalence, symptom patterns, and severity among disorders,
all α-synucleinopathies have in common autonomic nervous system dysfunctions,
which reduce quality of life. Frequent symptoms among α-synucleinopathies include
constipation, urinary and sexual dysfunction, and cardiovascular autonomic symptoms
such as orthostatic hypotension, supine hypertension, and reduced heart rate variability.
Symptoms due to autonomic dysfunction can appear before motor symptom onset,
particularly inMSA and PD, hence, detection and quantitative analysis of these symptoms
can enable early diagnosis and initiation of treatment, as well as identification of at-risk
populations. While patients with PD, DLB, and MSA show both central and peripheral
nervous system involvement of α-synuclein pathology, pure autonomic failure (PAF)
is a condition characterized by generalized dysregulation of the autonomic nervous
system with neuronal cytoplasmic α-synuclein inclusions in the peripheral autonomic
small nerve fibers. Patients with PAF often present with orthostatic hypotension, reduced
heart rate variability, anhydrosis, erectile dysfunction, and constipation, without motor
or cognitive impairment. These patients also have an increased risk of developing an
α-synucleinopathy with central involvement, such as PD, DLB, or MSA in later life,
possibly indicating a pathophysiological disease continuum. Pathophysiological aspects,
as well as developments in diagnosing and treating dysautonomic symptoms in patients
with α-synucleinopathies are discussed in this review.
Keywords: autonomic dysfunction, α-synucleinopathies, Parkinson disease, dementia with Lewy bodies, multiple
system atrophy, pure autonomic failure, dysautonomia
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INTRODUCTION
The α-synucleinopathies are neurodegenerative diseases charac-
terized by the abnormal accumulation of α-synuclein aggregates
in neurons and glial cells. These include, in order of prevalence:
Parkinson’s disease (PD), dementia with Lewy bodies (DLB),
and multiple system atrophy (MSA), as well as various rare
neuroaxonal dystrophies (1). A highly related condition, pure
autonomic failure (PAF), features generalized dysregulation
of the autonomic nervous system, with neuronal cytoplasmic
α-synuclein inclusions in the peripheral autonomic small nerve
fibers, and is regarded as a high-risk condition to develop PD,
DLB, or MSA (2, 3).
Dysautonomic symptoms are frequently found in the various
α-synucleinopathies, and can occur in any stage of the disease,
even in their prodromal states. Autonomic dysfunction includes
symptoms such as orthostatic hypotension (OH), reduced
heart rate variability, supine hypertension, constipation, fecal
incontinence, urinary, and sexual dysfunction. These symptoms
are originated by the damage to distinct components of the
central and peripheral autonomic nervous system (4–7).
Deposits of α-synuclein accumulate first in peripheral nerves,
including those in the skin and enteric mucosa, advancing
toward the brain through the vagal and olfactory nerves and
progressing through the encephalon, in a determined pattern
according to the particular disease phenotype (1, 8–10). This
pathological progression can explain the early apparition of
non-motor symptoms, among them, autonomic nervous system
dysfunction (11, 12).
Dysautonomic manifestations of the specific α-
synucleinopathies are caused by the involvement of various
components of the autonomous nervous system. In PD,
cardiovascular autonomic dysfunction is related to a loss of
peripheral noradrenergic innervation, while constipation most
likely reflects direct involvement of the enteric nervous system
neurons. In MSA, dysautonomic symptoms are mostly related
to degeneration of preganglionic autonomic neurons of the
brainstem and spinal cord (13).
Recently, the identification of α-synuclein deposits in skin
biopsies has opened a window to better understand autonomic
denervation, as well as providing a sensitive and specific
biomarker for early diagnosis of the α-synucleinopathies, with a
strong correlation between α-synuclein load in cutaneous small
fibers and measures of cardiovascular autonomic function, and
skin pilomotor and sudomotor responses (10, 14–17).
PREVALENCE AND IMPACT OF
AUTONOMIC DYSFUNCTION
IN α-SYNUCLEINOPATHIES
PD is the second most-common neurodegenerative disease,
affecting 2–3% of the population above 65 years of age (18). The
prevalence of autonomic dysfunction in PD ranges between 50
and 70% (19–21). The most common dysautonomic symptoms
in PD are constipation, urinary dysfunction, and OH (20).
Dysautonomic symptoms have been proposed as part of the
criteria for prodromal PD, together with REM sleep behavior
disorder, molecular neuroimaging biomarkers, sub-threshold
parkinsonism, hyposmia, depression, and anxiety (12, 22). In PD,
dysautonomic syndromes have a heterogeneous presentation,
and their progression is not predictable, however, their presence
is associated with a deterioration in autonomy and quality of life,
regardless of the duration of the disease, cognitive decline, or the
severity of motor symptoms (5, 23).
DLB is the secondmost frequent neurodegenerative dementia,
affecting up to 0.7% of the population above 60 years of age, and
causing up to 24% of the total cases of dementia worldwide (24).
Dysautonomic symptoms are a part of the supportive clinical
features for the diagnostic criteria of this disease, and their
estimated prevalence is 62% (21, 25, 26). In DLB, autonomic
dysfunction can be a prodromal feature (11): in a case series of
90 patients with DLB, more than half displayed dysautonomic
symptoms (particularly OH) prior to the onset of cognitive
impairment (27).
MSA is an infrequent cause of dementia, with an incidence of
3 per 100,000 person-years in people above 50 years of age (28).
Dysautonomia is a core clinical criteria for this condition, which
subdivides into two phenotypes, depending on the predominance
of motor symptoms (cerebellar or parkinsonian), additional
to autonomic dysfunction (29). Autonomic dysfunction can
precede the onset of motor symptoms of MSA in up to 50% of
patients (30). Urinary dysfunction and OH are the most frequent
dysautonomic symptoms ofMSA, with an earlier onset of urinary
symptoms, particularly in the cerebellar phenotype (30, 31).
In MSA, severe dysautonomia and the early combination of
dysautonomic and motor symptoms are poor prognostic factors,
regardless of the phenotype (32).
A syndrome that deserves special attention in the study of
α-synucleinopathies is pure autonomic failure (PAF). PAF is
defined by the presence of chronic OH, without clinical signs
of central neurodegeneration (2, 33). Patients with PAF can also
display supine hypertension, constipation, urinary symptoms
and thermic dysregulation (7). In a 4-year follow-up study of
100 patients with PAF, 34% progressed to an α-synucleinopathies.
The risk of conversion was seven times higher in subjects that,
in addition to dysautonomic symptoms, presented a REM sleep
behavior disorder. Patients that progressed to PD or DLB had a
higher prevalence of hyposmia, worse response to the head-up
tilt test, and a longer disease course; while those that converted to
MSA had a younger onset dysautonomia and a higher prevalence
of urinary and bowel dysfunction. The subjects that did not
convert to any of these diseases had significantly lower levels
of blood epinephrine (6). α-synuclein has also been found in
skin biopsies and postganglionic sympathetic neurons of PAF
patients, reflecting a common pathological precursor between
PAF and other α-synucleinopathies (13, 34). An autonomic-only
presentation of MSA can be indistinguishable from PAF, specially
in the early stages (35).
SPECIFIC DYSAUTONOMIC SYMPTOMS
IN α-SYNUCLEINOPATHIES
OH is the main clinical feature of cardiovascular autonomic
dysfunction, and it is defined as sustained drop in systolic
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pressure of at least 20mm Hg and/or a sustained diastolic
drop of at least 10mm Hg within the first 3min after standing
up (36, 37). This time cut-off might not be sensitive for α-
synucleinopathies, in which the presentation is most commonly
that of delayed OH, therefore, measuring blood pressure for
at least 10min has been recommended (36). Delayed OH has
been documented as a risk factor for α-synucleinopathies, and
frequently progresses to OH with a high associated mortality
(38). Noradrenergic cardiac and extracardiac denervation, as
well as the lack of arterial baroreflexes in α-synucleinopathies
are causal factors of this symptom (39, 40). The loss of
baroreceptor sensitivity has been documented through spectral
analysis of heart rate (R-R interval) and systolic arterial pressure
variability in PAF (41) and PD (42), even before the onset
of OH (43, 44). A functional association between OH and
cognitive decline in α-synucleinopathies has been documented,
given that OH aggravates neural damage because of cerebral
hypoperfusion (36, 45, 46). OH affects 30–60% of PD patients,
and has been linked to an elevated frequency of falls, detriment
of physical activity, and use of health care services, even
if OH is asymptomatic (23, 29, 47, 48). The frequency of
OH varies according to the stage of the disease, from 14%
in early-stage PD patients to 52% in later cases or older
individuals (49–51). Around 68% of patients with DLB display
OH, and about 17% suffer associated syncope (26, 36, 52). OH
affects around 43% of patients with MSA from early stages
of the disease, and of these, 50% also display post-prandial
hypotension, as well as nocturnal and supine hypertension
(30, 53, 54). This condition is more frequent and more severe
in the cerebellar phenotype of MSA when compared to the
parkinsonian subtype (55).
Constipation is defined as a frequency of less than three bowel
movements in 1 week (56). Between 54 and 90% of PD patients
suffer from constipation, and out of these, 48% report the onset of
constipation up to 10 years prior to the onset of motor symptoms
(20, 57, 58). Constipation is more frequent in patients with a
rigid-bradykinetic phenotype and is related to the presence of
neuropsychiatric symptoms, such as anxiety, depression, and
insomnia (57). Constipation may start even before in MSA than
in PD (59). In patients with DLB, a frequency of 30% has been
documented (60).
In patients with α-synucleinopathies, the gastrointestinal
function is disturbed at all levels. Dysphagia in PD and DLB
tends to be mild, and appears in later stages of the disease,
while in MSA it can be early and severe. Aspiration pneumonia
is a common cause of death in α-synucleinopathies, and
higher gastrointestinal symptoms (attributable to esophageal
dysmotility and gastroparesis) diminish the quality of life of these
patients (58, 61).
Urinary dysfunction is present in up to 71% of PD patients,
mostly with nocturia and altered urinary frequency (62). In
a Japanese study that included 32 patients with DLB, a
90% prevalence of urinary dysfunction was found, with a
predominance of nocturia, followed by urinary incontinence and
detrusor hyperactivity (63). Up to 96% of MSA patients display
urinary symptoms, which tend to be more severe than in PD,
and 60% start before the onset of motor symptoms (with a mean
of 4 years before diagnosis), mostly with post-residual volume
alterations (53, 62, 64).
Erectile dysfunction is defined as the incapacity to achieve or
maintain a penile erection long enough to allow a sexual relation
(65). In a 7-year follow-up study of 3,153 patients with erectile
dysfunction, a 1.52-times higher risk of PD was found, with an
even higher risk if cardiovascular risk factors, such as diabetes
or hypertension, was concurrent (66). Erectile dysfunction is
present in up to 97% of men diagnosed with MSA, and it is
the initial symptom in 48% of male patients, preceding motor
symptoms for as long as a decade (30, 59, 64). Female sexual
dysfunction has been less studied in α-synucleinopathies, but a
higher prevalence of this disorder has been found in female PD
patients than in age-matched controls, and it is related to older
age and a higher severity of depressive symptoms (67).
CLINICAL ASSESSMENT OF AUTONOMIC
DYSFUNCTION
IN α-SYNUCLEINOPATHIES
Clinical tests designed to measure the end-organ responses to the
autonomic nervous systems can be used to quantitatively analyze
autonomic dysfunction, playing an important role in the clinical
assessment of α-synucleinopathies.
Tests of cardiovagal function include heart rate variability
with deep breathing, postural changes (such as the head-up tilt
test), or the Valsalva maneuver, in which the patient forcefully
exhales into a sphygmomanometer with an open glottis at a
pressure of 40 mmHg for 15 s. Sympathetic adrenergic function
can be assessed by measuring blood pressure response to postural
change, Valsalva maneuver or isometric exercise, as well as
by the cold pressor test, in which the subject is instructed
to immerse his or her hand in ice water for 1min (68). The
decrease of heart rate and blood pressure variability can be
accurately demonstrated through power spectrum techniques,
which provide a quantitative assessment of said variability
(41, 43, 69, 70). Ambulatory blood pressure monitoring can
also provide sensitive markers of autonomous nervous system
failure, such as post-prandial hypotension and nocturnal/supine
hypertension (71, 72).
Clinical assessments of sudomotor function include
thermoregulatory sweat testing, quantitative sudomotor axon
reflex testing, silicone impression, the sympathetic skin response,
the acetylcholine sweat-spot test, and quantitative direct and
indirect axon reflex testing, as well as electromyographic skin
potentials (73, 74). Cutaneous autonomic pilomotor testing, in
which iontophoresis of phenylephrine induces a local neurogenic
pilomotor erection (“goose bumps”) as a measure of functional
integrity of autonomic skin nerve fibers, is an approach to
capture the progression of autonomic nerve dysfunction and
α-synuclein deposition (75).
Differential diagnosis of the parkinsonian subtype of MSA
and PD or other parkinsonian syndromes is mostly based
on the evaluation of autonomic dysfunction (9, 30). Clinical
autonomic cardiovascular tests can distinguishMSA and PDwith
a sensitivity of 91% and a specificity of 92%. (123)-I-myocardial
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metaiodobenzyguanidine (MIBG) scintigraphy can distinguish
these entities with a sensitivity of 90% and specificity of 82% (7,
30). Cardiovagal baroreflex is also sensitive for the differentiation
between MSA and PD, being disproportionally affected in MSA
(76). Added sweating and thermoregulation tests have also been
found to improve differential diagnostic reliability (77, 78).
MOLECULAR AND CELLULAR ASPECTS
OF AUTONOMIC DYSFUNCTION
IN α-SYNUCLEINOPATHIES
Mutations in the gene encoding for α-synuclein, SNCA, as
well as in some of the genes collectively referred to as
PARK (including the LRRK2 and VPS35 genes), have been
associated with variants of autosomal dominant PD, and
others such as PARK2, PINK1, and PARK7 to autosomal
recessive PD. Although the mechanism has not been completely
clarified, it is known that mutated proteins have different
roles in autophagy and the degradation of nerve cells.
Familial cases of DLB have been associated with mutations
in the PARK, SNCA, SNCB, and LRRK2 genes. In the rare
familial cases of MSA, there is a reported association to
SNCA and COQ2 genes. Autonomic dysfunction has been
associated with six SNCA mutations in different groups,
including subjects with PAF prior to the onset of motor
symptoms (79, 80).
TABLE 1 | Pharmacological and non-pharmacological strategies for dysautonomic symptoms in α-synucleinopathies.
Dysautonomic symptom Pharmacological strategy Non-pharmacological strategy
Orthostatic hypotension • Expansion of intravascular volume with fludrocortisone
(58)
• Increase of peripheral vascular resistance with
midodrine, droxidopa or norepinephrine transporter
inhibitors, such as atomoxetine, yohimbine, ergotamine,
and caffeine (58, 83)
• Potentiation of peripheral cholinergic neurotransmission
(84)
• Domperidone in non-cardiac patients (85)
• Discontinue antihypertensive and other medications that can cause
orthostatic hypotension (84)
• Physical contermaneuvers (e.g., standing with legs crossed, squatting,
active tensing of leg muscles, breathing-related maneuvers to increase
inspiratory resistance, and avoiding getting up too quickly or standing
motionless) (58, 86)
• Use of compression stockings (58)
• Increase the consumption of water and drinks with caffeine during meals
(58, 86)
• Eat small, frequent meals (86)
• Physical activity such as water exercise, recumbent bicycling, or rowing
(86)
• Avoid alcohol consumption (86)
• Avoid situations that increase core body temperature such as prolonged
hot showers (86)
• Plantar mechanical stimulation is a promising approach for the
regulation of heart rate variability in PD (42, 69)
Supine hypertension • Antihypertensives: captoptil, nevibolol, clonidine,
hydralazine, losartan (58)
• Clonidine, nitroglycerin patches, and short-acting
nifedipine (83, 84)
• At night, tilt the bed to achieve an angle of 30 or 45 degrees (58)
• The application of abdominal local heat could be of benefit (58)
Constipation • Bulk laxatives, like psyllium or methylcellulose (58)
• Osmotic laxatives (polyethylene glycol, magnesium,
lactuslose) (58)
• Probiotics, high fiber diets, olive oil
• Adequate hydration (58)
• Physical activity (87)
Dysphagia and excessive
salivation
• Botulinum toxin in the distal esophagus could improve
dysphagia (58)
• Vocal fold augmentation, including injection
laryngoplasty (88)
• In patients with sialorrhea, treatment with glycopyrrolate
and the local application of anticholinergics, as drops of
sublingual atropine or ipatropium spray (58)
• Reduce the volume of food (58)
• Eat slowly (58)
• Eat foods with a more liquid consistency (58)
• Speech and swallowing therapy (61, 89)
Gastroparesis • Dopamine blockers like metoclopramide, itopride (58)
• Motilin receptor agonists such as erythromycin (58)
• Serotonergic agonists like cisapride (58)
• Low fat diet (58)
• Small but frequent meals (58)
Urinary dysfunction • B3-adrenergic agonists like mirabregon (58)
• Antimuscarinic agents such as oxybutynin, atripine,
scopolamine (58)
• Alpha-adrenergic blockers like tamsolusin (58)
• Biofeedback (58)
• Deep brain stimulation of the subthalamic nulcei (90)
Erectile dysfunction • Phosphodiesterase type 5 (PDE-5) inhibitors, with
caution because of potentially severe hypotension (58)
• Intraurethral prostaglandin suppositories (58)
• Psychotherapy, sex counseling seeking “pleasure oriented” activity
instead of “goal-oriented” intercourse (91)
• Vacuum pump devices (58)
• Surgical placement of penis prosthesis (58)
Female sexual dysfunction • Hormonal replacement therapy (58) • Psychotherapy, sex counseling seeking “pleasure oriented” activity
instead of “goal-oriented” intercourse (58, 91)
• Vaginal lubrication (58)
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The families carrying PD with a chromosomal triplication
of SNCA present OH with evidence of sympathetic cardiac
denervation and frequent associated falls up to 3 years before the
onset of the disease. However, there are triplications of SNCA
without documented autonomic dysfunctions. This phenotypic
heterogeneity could be explained by the variability in the genomic
size of SNCA triplications, meaning that different genes could
be involved. In addition to OH, other dysautonomic symptoms,
such as urinary incontinence and severe constipation of early
onset, are more frequent in triplications of SNCA compared
to duplications. A sympathetic cardiac denervation has also
been found in heterozygous carriers with biallelic mutations of
PARK2, causal of the most common autosomal recessive form
of PD. Other mutations in the LRRK gene are also associated
with different autonomic profiles in PD, with symptoms such as
constipation, neurogenic bladder, and erectile dysfunction (79).
The central autonomic network and preganglionic
sympathetic and parasympathetic neurons are variably
affected in the different α-synucleinopathies. In PD and
DLB, the dorsal motor nucleus of the vagus nerve, and in MSA
the ventrolateral medulla, hypothalamus and preganglionic
neurons are key structures affected that explain the origin of
autonomic dysfunction (13). PAF involves generalized loss of
sympathoadrenomedullary cells, as reflected by plasma levels
of catechols and metanephrines, in contrast to MSA and PD,
where adrenomedullary cells seem to remain intact, but organ-
selective sympathetic denervation occurs (81). Furthermore,
α-synuclein-containing glial cytoplasmic inclusions have been
found in the Oluf ’s nucleus of MSA-affected individuals,
which might account for early urinary, defecatory and sexual
symptoms (64).
In brain tissue, an abnormal accumulation of α-synuclein
has been found in the left posterior part of the insula of
patients with PD, correlated with the presence of OH. The
inclusions of α-synuclein in the hypothalamus of patients with
PD may be linked to hypothalamic dysfunction, resulting from
lesions in the thermoregulatory centers of the preoptic area,
causing hypothermia, episodes of sweating, or hypohidrosis. In
MSA, the neurons of the paraventricular nucleus project to
the intermediolateral cell column, and their dysfunction can
contribute to the lack of control of sympathetic function, causing
OH. Both MSA and DLB show a loss of tyrosine hydroxylase
in neurons of the periaqueductal gray matter, which is related
to autonomic cardiovascular and urinary dysfunction (13). With
respect to constipation and gastrointestinal symptoms presented
by patients, α-synuclein inclusions have been detected in colon
biopsies up to 8 years before the onset of motor symptoms of PD
and, although the studies are not consistent, it is believed that the
presence of extracellular α-synuclein is associated with acute and




Dysautonomic symptoms are among the most debilitating
in α-synucleinopathies, but, when recognized, they can be
treated using both pharmacological and non-pharmacological
strategies, including the suspension of potentially causing or
aggravating medications, and patient education. Table 1 shows
the therapeutic strategies for this group of symptoms.
CONCLUSIONS
Dysautonomic symptoms frequently occuring in α-
synucleinopathies comprise cardiovascular, gastrointestinal,
urogenital and thermoregulatory disturbances. These symptoms
reduce quality of life and worsen prognosis. The understanding
of their pathophysiology, as well as the detection of α-synuclein
deposition and autonomic dysfunction in the premotor stages of
α-synucleinopathies may be key for identifying novel treatment
targets and improving clinical outcomes. While causative
treatment is not yet available, improvement of quality of
life can be achieved by personalized symptomatic treatment
regimens, which includes both and pharmacological and
non-pharmacological strategies.
AUTHOR CONTRIBUTIONS
JM-V: oversight of teamwork, literature search and review of
articles, writing of abstract and parts 2, 3, and 4; JF-V: literature
search and review of articles, writing of parts 1, 2, and 4;
EB-V: review of articles, writing of parts 5 and 6; AS-O and
B-MI: proofreading, expert advice on theoretical and clinical
aspects; TS: proofreading, expert advice on theoretical and
clinical aspects, identification of additional relevant papers.
FUNDING
We acknowledge support by the Open Access Publication Funds
of the SLUB/TU Dresden.
REFERENCES
1. McCann H, Stevens CH, Cartwright H, Halliday GM. α-
Synucleinopathy phenotypes. Park Relat Disord. (2014) 20(Suppl.1):S62–7.
doi: 10.1016/S1353-8020(13)70017-8
2. Coon EA, Low PA. Pure autonomic failure without alpha-
synuclein pathology: an evolving understanding of a heterogeneous
disease. Clin Auton Res. (2017) 27:67–8. doi: 10.1007/s10286-
017-0410-1
3. Kaufmann H, Goldstein DS. Editorial: pure autonomic failure: a restricted
lewy body synucleinopathy or early parkinson disease? Neurology. (2010)
74:536–7. doi: 10.1212/WNL.0b013e3181d26982
4. Palma J-A. Autonomic dysfunction in Parkinson’s disease and other
synucleinopathies: introduction to the series. Mov Disord. (2018) 33:347–8.
doi: 10.1002/mds.27347
5. Leclair-Visonneau L,Magy L, Volteau C, Clairembault T, Le Dily S, Préterre C,
et al. Heterogeneous pattern of autonomic dysfunction in Parkinson’s disease.
J Neurol. (2018) 265:933–41. doi: 10.1007/s00415-018-8789-8
Frontiers in Neurology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 363
Mendoza-Velásquez et al. Autonomic Dysfunction in α-Synucleinopathies
6. Kaufmann H, Norcliffe-Kaufmann L, Palma J, Biaggioni I, Low PA, Singer W,
et al. Natural history of pure autonomic failure: a United States prospective
cohort. Ann Neurol. (2017) 81:287–97. doi: 10.1002/ana.24877
7. Merola A, Espay AJ, Zibetti M, Romagnolo A, Rosso M. Pure autonomic
failure versus prodromal dysautonomia in Parkinson’ s disease :
insights from the bedside. Mov Disord. (2016) 4:141–44. doi: 10.1002/
mdc3.12360
8. Braak H, Tredici K Del, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E.
Staging of brain pathology related to sporadic Parkinson’ s disease staging of
brain pathology related to sporadic Parkinson’ s disease. Neurobiol Aging.
(2003) 4580:197–211. doi: 10.1016/S0197-4580(02)00065-9
9. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The differential
diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int. (2016)
113:61–9. doi: 10.3238/arztebl.2016.0061
10. Doppler K, Ebert S, Üçeyler N, Trenkwalder C, Ebentheuer J,
Volkmann J, et al. Cutaneous neuropathy in Parkinson’s disease: a
window into brain pathology. Acta Neuropathol. (2014) 128:99–109.
doi: 10.1007/s00401-014-1284-0
11. Fujishiro H, Nakamura S, Sato K, Iseki E. Prodromal dementia with Lewy
bodies. Geriatr Gerontol Int. (2015) 15:817–26. doi: 10.1111/ggi.12466
12. Mahlknecht P, Gasperi A, Djamshidian A, Kiechl S, Stockner H, Willeit P, et
al. Performance of the Movement Disorders Society criteria for prodromal
Parkinson’s disease: a population-based 10-year study. Mov Disord. (2018)
33:405–13. doi: 10.1002/mds.27281
13. Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of
autonomic dysfunction in synucleinopathies. Mov Disord. (2018) 33:349–58.
doi: 10.1002/mds.27186
14. Siepmann T, Penzlin AI, Illigens BMW, Reichmann H. Should skin biopsies
be performed in patients suspected of having Parkinson’s disease? Parkinsons
Dis. (2017) 2017:6064974. doi: 10.1155/2017/6064974
15. Siepmann T, Illigens BMW, Barlinn K. Alpha-synuclein in cutaneous
small nerve fibers. Neuropsychiatr Dis Treat. (2016) 12:2731–5.
doi: 10.2147/NDT.S117423
16. Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M,
et al. A new potential biomarker for dementia with Lewy bodies. Neurology.
(2017) 89:318–26. doi: 10.1212/WNL.0000000000004146
17. Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic
discrimination of cutaneous α-synuclein deposition in Parkinson disease.
Neurology. (2016) 87:505–12. doi: 10.1212/WNL.0000000000002919
18. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann
J, et al. Parkinson disease. Nat Rev Dis Prim. (2017) 3:17013.
doi: 10.1038/nrdp.2017.13
19. Merola A, Romagnolo A, Comi C, Rosso M, Artusi CA, Zibetti M, et al.
Prevalence and burden of dysautonomia in advanced Parkinson’s disease.Mov
Disord. (2017) 32:796–7. doi: 10.1002/mds.26970
20. Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C,
Alvarez-Sanchez M, Arakaki T, et al. Assessing the non-motor symptoms
of Parkinson’s disease: MDS-UPDRS and NMS scale. Eur J Neurol. (2015)
22:37–43. doi: 10.1111/ene.12165
21. Walter BL. Cardiovascular autonomic dysfunction in patients with movement
disorders. Cleve Clin J Med. (2008) 75:S54.
22. Rutten S, Ghielen I, Vriend C, Hoogendoorn AW, Berendse HW, Leentjens
AFG, et al. Anxiety in Parkinson’s disease: symptom dimensions and overlap
with depression and autonomic failure. Parkinsonism Relat Disord. (2015)
21:189–93. doi: 10.1016/j.parkreldis.2014.11.019
23. Merola A, Romagnolo A, RossoM, Suri R, Berndt Z,Maule S, et al. Autonomic
dysfunction in Parkinson’s disease: a prospective cohort study. Mov Disord.
(2018) 33:391–7. doi: 10.1002/mds.27268
24. Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, et
al. The prevalence and incidence of dementia with Lewy bodies: a systematic
review. Can J Neurol Sci. (2016) 43:S83–95. doi: 10.1017/cjn.2016.2
25. Mckeith IG, Sci M, Boeve BF, Dickson DW, Halliday G, Taylor J-P, et
al. Diagnosis and management of dementia with Lewy bodies Fourth
consensus report of the DLB Consortium. Neurology. (2017) 89:88–100.
doi: 10.1212/WNL.0000000000004058
26. Horimoto Y, Matsumoto M, Akatsu H, Ikari H, Kojima K, Yamamoto T, et
al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol. (2003)
250:530–3. doi: 10.1007/s00415-003-1029-9
27. Fujishiro H, Iseki E, Nakamura S, Kasanuki K, Chiba Y, Ota K, et al. Dementia
with Lewy bodies: early diagnostic challenges. Psychogeriatrics. (2013) 13:128–
38. doi: 10.1111/psyg.12005
28. Krismer F, Wenning GK. Multiple system atrophy: insights into a rare
and debilitating movement disorder. Nat Rev Neurol. (2017) 13:232–43.
doi: 10.1038/nrneurol.2017.26
29. Laurens B, Vergnet S, Lopez MC, Foubert-Samier A, Tison F, Fernagut PO, et
al. Multiple system atrophy - state of the art. Curr Neurol Neurosci Rep. (2017)
17:5. doi: 10.1007/s11910-017-0751-0
30. Bhatia KP, Stamelou M. Nonmotor features in atypical Parkinsonism. 1st ed.
Int Rev Neurobiol. (2017) 1285–301. doi: 10.1016/bs.irn.2017.06.001
31. Zheng J, Yang X, Chen Y, Zhao Q, Tian S, Huang H, et al. Onset of bladder
and motor symptoms in multiple system atrophy: differences according to
phenotype. Clin Auton Res. (2017) 27:103–6. doi: 10.1007/s10286-017-0405-y
32. Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive
supranuclear palsy and multiple system atrophy: a systematic review
and meta-analysis. J Neurol Neurosurg Psychiatry. (2017) 88:402–11.
doi: 10.1136/jnnp-2016-314956
33. Isonaka R, Holmes C, Cook GA, Sullivan P, Sharabi Y, Goldstein DS. Pure
autonomic failure without synucleinopathy. Clin Auton Res. (2017) 27:97–
101. doi: 10.1007/s10286-017-0404-z
34. Shishido T, Ikemura M, Obi T, Yamazaki K, Terada T, Sugiura A,
et al. Alpha-synuclein accumulation in skin nerve fibers revealed by
skin biopsy in pure autonomic failure. Neurology. (2010) 74:608–10.
doi: 10.1212/WNL.0b013e3181cff6d5
35. Palma J-A, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system
atrophy. Auton Neurosci. (2018) 211:15–25. doi: 10.1016/j.autneu.2017.10.007
36. Joseph A, Wanono R, Flamant M, Vidal-Petiot E. Orthostatic hypotension: a
review. Nephrol Ther. (2017) 13:S55–67. doi: 10.1016/j.nephro.2017.01.003
37. Scorza FA, Fiorini AC, Scorza CA, Finsterer J. Cardiac abnormalities
in Parkinson’s disease and Parkinsonism. J Clin Neurosci. (2018) 53:1–5.
doi: 10.1016/j.jocn.2018.04.031
38. Gibbons CH, Freeman R. Clinical implications of delayed
orthostatic hypotension. Neurology. (2015) 85:1362–7.
doi: 10.1212/WNL.0000000000002030
39. Norcliffe-Kaufmann L, Kaufmann H, Palma J-A, Shibao CA, Biaggioni I,
Peltier AC, et al. Orthostatic heart rate changes in patients with autonomic
failure caused by neurodegenerative synucleinopathies. Ann Neurol. (2018)
83:522–31. doi: 10.1002/ana.25170
40. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease:
from pathophysiology to pathogenesis. Neurobiol Dis. (2012) 46:572–80.
doi: 10.1016/j.nbd.2011.10.025
41. Furlan R, Piazza S, Bevilacqua M, Turiel M, Norbiato G, Lombardi F, et al.
Pure autonomic failure: complex abnormalities in the neural mechanisms
regulating the cardiovascular system. J Auton Nerv Syst. (1995) 51:223–35.
doi: 10.1016/0165-1838(94)00135-7
42. Barbic F, Galli M, Dalla Vecchia L, Canesi M, Cimolin V, Porta A, et al.
The effects of mechanical stimulation of the feet on gait and cardiovascular
autonomic control in Parkinson’s disease. Am J Physiol Circ Physiol. (2014)
116:495–503. doi: 10.1152/japplphysiol.01160.2013
43. Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costantino G, et al.
Early abnormalities of vascular and cardiac autonomic control in Parkinson’s
disease without orthostatic hypotension. Hypertension. (2007) 49:120–6.
doi: 10.1161/01.HYP.0000250939.71343.7c
44. Strano S, Fanciulli A, Rizzo M, Marinelli P, Palange P, Tiple D, et al.
Cardiovascular dysfunction in untreated Parkinson’s disease: amulti-modality
assessment. J Neurol Sci. (2016) 370:251–5. doi: 10.1016/j.jns.2016.09.036
45. Udow SJ, Robertson AD, Macintosh BJ, Espay AJ, Rowe JB, Lang AE, et
al. “Under pressure”: is there a link between orthostatic hypotension and
cognitive impairment in α-synucleinopathies? J Neurol Neurosurg Psychiatry.
(2016) 87:1311–21. doi: 10.1136/jnnp-2016-314123
46. Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb
A. Effects of orthostatic hypotension on cognition in Parkinson disease.
Neurology. (2017) 88:17–24. doi: 10.1212/WNL.0000000000003452
47. Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR, Wissel BD,
Larkin S, et al. Orthostatic hypotension in Parkinson’s disease: does
it matter if asymptomatic? Parkinsonism Relat Disord. (2016) 33:65–71.
doi: 10.1016/j.parkreldis.2016.09.013
Frontiers in Neurology | www.frontiersin.org 6 April 2019 | Volume 10 | Article 363
Mendoza-Velásquez et al. Autonomic Dysfunction in α-Synucleinopathies
48. Mol A, Reijnierse EM, Hoang PTSB, van Wezel RJA, Meskers CGM, Maier
AB. Orthostatic hypotension and physical functioning in older adults: a
systematic review and meta-analysis. Ageing Res Rev. (2018) 48:122–44.
doi: 10.1016/j.arr.2018.10.007
49. Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini
S, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol.
(2003) 60:1400–4. doi: 10.1001/archneur.60.10.1400
50. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et
al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and
their impact on quality of life in Parkinson’s disease. Mov Disord Off J Mov
Disord Soc. (2009) 24:1641–9. doi: 10.1002/mds.22643
51. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllylä VV.
Orthostatic hypotension, balance and falls in Parkinson’s disease.Mov Disord
Off J Mov Disord Soc. (2009) 24:745–51. doi: 10.1002/mds.22457
52. Bengtsson-Lindberg ME, Larsson VS, Minthon LB, Wattmo CAS, Londos
EY. Evaluation of systolic and diastolic hypotension in dementia with Lewy
bodies and Alzheimer’s disease. Heal Aging Clin Care Elder. (2013) 5:33–9.
doi: 10.4137/HACCE.S12670
53. Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, et al.
Urinary dysfunction and orthostatic hypotension in multiple system atrophy:
which is the more common and earlier manifestation? J Neurol Neurosurg
Psychiatry. (2000) 68:65–9. doi: 10.1136/jnnp.68.1.65
54. Fanciulli A, Göbel G, Ndayisaba JP, Granata R, Duerr S, Strano S, et al. Supine
hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton
Res. (2016) 26:97–105. doi: 10.1007/s10286-015-0336-4
55. Wenning GK, Granata R, Krismer F, Dürr S, Seppi K, Poewe W, et al.
Orthostatic hypotension is differentially associated with the cerebellar versus
the parkinsonian variant of multiple system atrophy: a comparative study.
Cerebellum. (2012) 11:223–6. doi: 10.1007/s12311-011-0299-5
56. Andy UU, Vaughan CP, Burgio KL, Alli FM, Goode PS, Markland AD. Shared
risk factors for constipation, fecal incontinence, and combined symptoms in
older US adults. J Am Geriatr Soc. (2016) 64:e183–8. doi: 10.1111/jgs.14521
57. Gan J, Wan Y, Shi J, ZhouM, Lou Z, Liu Z. A survey of subjective constipation
in Parkinson’s disease patients in shanghai and literature review. BMCNeurol.
(2018) 18:1–9. doi: 10.1186/s12883-018-1034-3
58. Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson
disease and other synucleinopathies. Mov Disord. (2018) 33:372–90.
doi: 10.1002/mds.27344
59. Savica R, Bradley BF, Mielke MM. When do a-Synucleinopathies start?
An epidemiological timeline a review. JAMA Neurol. (2018) 75:503–9.
doi: 10.1001/jamaneurol.2017.4243
60. Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of
autonomic dysfunction on survival in patients with dementia with lewy
bodies and Parkinson’s disease with dementia. PLoS ONE. (2012) 7:e45451.
doi: 10.1371/journal.pone.0045451
61. Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. (2016)
31:24–32. doi: 10.1007/s00455-015-9671-9
62. Sakakibara R, Tateno F, Yamamoto T, Uchiyama T, Yamanishi
T. Urological dysfunction in synucleinopathies: epidemiology,
pathophysiology and management. Clin Auton Res. (2018) 28:83–101.
doi: 10.1007/s10286-017-0480-0
63. Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, et al.
Lower urinary tract function in dementia with Lewy bodies (DLB). Mov
Disord. (2015) 30:411–5. doi: 10.1002/mds.25985
64. McKay JH, Cheshire WP. First symptoms in multiple system atrophy. Clin
Auton Res. (2018) 28:215–21. doi: 10.1007/s10286-017-0500-0
65. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. (2013) 381:153–65.
doi: 10.1016/S0140-6736(12)60520-0
66. Yang Y, Liu H, Lin T, Kuo Y, Hsieh T. Relationship between erectile
dysfunction, comorbidity, and Parkinson’s disease: evidence from
a population-based longitudinal study. J Clin Neurol. (2017) 13:250.
doi: 10.3988/jcn.2017.13.3.250
67. Varanda S, Ribeiro da Silva J, Costa AS, Amorim de Carvalho C, Alves JN,
Rodrigues M, et al. Sexual dysfunction in women with Parkinson’s disease.
Mov Disord. (2016) 31:1685–93. doi: 10.1002/mds.26739
68. Freeman R, ChapleauMW. Testing the autonomic nervous system. In: Said G,
Krarup C, editors.Handbook of Clinical Neurology, 3rd ed. Elsevier BV (2013).
p. 115–36. doi: 10.1016/B978-0-444-52902-2.00007-2
69. Bassani T, Bari V, Marchi A, Tassin S, Dalla Vecchia L, Canesi M, et al. Model-
free causality analysis of cardiovascular variability detects the amelioration
of autonomic control in Parkinson’s disease patients undergoing mechanical
stimulation. Physiol Meas. (2014) 35:1397. doi: 10.1088/0967-3334/
35/7/1397
70. Malliani A, Lombardi F, Pagani M. Power spectrum analysis of heart rate
variability: a tool to explore neural regulatory mechanisms. Br Heart J. (1994)
71:1. doi: 10.1136/hrt.71.1.1
71. Luciano GL, Brennan MJ, Rothberg MB. Post-prandial hypotension. Am J
Med. (2010) 123:281-e1. doi: 10.1016/j.amjmed.2009.06.026
72. Umehara T, Matsuno H, Toyoda C, Oka H. Clinical characteristics of supine
hypertension in de novo Parkinson disease. Clin Auton Res. (2016) 26:15–21.
doi: 10.1007/s10286-015-0324-8
73. Illigens BMW, Gibbons CH. Sweat testing to evaluate autonomic function.
Clin Auton Res. (2009) 19:79–87. doi: 10.1007/s10286-008-0506-8
74. Buchmann SJ, Penzlin AI, Kubasch ML, Illigens BMW, Siepmann T.
Assessment of sudomotor function. Clin Auton Res. (2018) 29:41–53.
doi: 10.1007/s10286-018-0530-2
75. Siepmann T, Pintér A, Buchmann SJ, Stibal L, Arndt M, Kubasch AS, et
al. Cutaneous autonomic pilomotor testing to unveil the role of neuropathy
progression in early Parkinson’s disease (CAPTURE PD): protocol for
a multicenter study. Front Neurol. (2017) 8:1–9. doi: 10.3389/fneur.
2017.00212
76. Roy S, Jaryal AK, Srivastava AK, Deepak KK. Cardiovagal baroreflex
sensitivity in Parkinson’s disease and multiple-system atrophy. J Clin Neurol.
(2016) 12:218–23. doi: 10.3988/jcn.2016.12.2.218
77. Pavy-LeTraon A, Brefel-Courbon C, Dupouy J, Ory-Magne F, Rascol O,
Senard JM. Combined cardiovascular and sweating autonomic testing to
differentiate multiple system atrophy from Parkinson’s disease. Neurophysiol
Clin. (2018) 48:103–10. doi: 10.1016/j.neucli.2017.11.003
78. Augustis S, Saferis V, Jost WH. Autonomic disturbances including impaired
hand thermoregulation in multiple system atrophy and Parkinson’s disease. J
Neural Transm. (2017) 124:965–72. doi: 10.1007/s00702-016-1665-8
79. Chelban V, Vichayanrat E, Schottlaende L, Iodice V, Houlden H. Autonomic
dysfunction in genetic forms of synucleinopathies. Mov Disord. (2018)
33:359–71. doi: 10.1002/mds.27343
80. da Silva CP, de Abreu GM, Cabello Acero PH, Campos M, Pereira JS,
Sarah SR, et al. Clinical profiles associated with LRRK2 and GBA mutations
in Brazilians with Parkinson’s disease. J Neurol Sci. (2017) 381:160–4.
doi: 10.1016/j.jns.2017.08.3249
81. Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels
of catechols and metanephrines in neurogenic orthostatic hypotension.
Neurology. (2003) 60:1327–32. doi: 10.1212/01.WNL.0000058766.
46428.F3
82. Sharma A, Kurek J, Morgan JC, Wakade C, Rao SSC. Constipation
in Parkinson’s disease: a nuisance or nuanced answer to the
pathophysiological puzzle? Curr Gastroenterol Rep. (2018) 20:1–9.
doi: 10.1007/s11894-018-0609-x
83. Shibao CA, Kaufmann H. Pharmacotherapy of cardiovascular autonomic
dysfunction in Parkinson disease. CNS Drugs. (2017) 31:975–89.
doi: 10.1007/s40263-017-0473-5
84. Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S,
et al. The recommendations of a consensus panel for the screening, diagnosis,
and treatment of neurogenic orthostatic hypotension and associated
supine hypertension. J Neurol. (2017) 264:1567–82. doi: 10.1007/s00415-
016-8375-x
85. Bacchi S, Chim I, Kramer P, Postuma RB. Domperidone for hypotension in
Parkinson’s disease: a systematic review. J Parkinsons Dis. (2017) 7:603–17.
doi: 10.3233/JPD-171209
86. Arnold AC, Raj SR. Orthostatic hypotension: a practical approach
to investigation and management. Can J Cardiol. (2017) 33:1725–8.
doi: 10.1016/j.cjca.2017.05.007
87. Amara AW, Memon AA. Effects of exercise on non-motor
symptoms in Parkinson’s disease. Clin Ther. (2018) 40:8–15.
doi: 10.1016/j.clinthera.2017.11.004
88. Howell RJ, Webster H, Kissela E, Gustin R, Kaval F, Klaben B, et
al. Dysphagia in Parkinson’s disease improves with vocal augmentation.
Dysphagia. (2019). doi: 10.1007/s00455-019-09982-z. [Epub ahead of print].
Frontiers in Neurology | www.frontiersin.org 7 April 2019 | Volume 10 | Article 363
Mendoza-Velásquez et al. Autonomic Dysfunction in α-Synucleinopathies
89. Speyer R, Baijens L, Heijnen M, Zwijnenberg I. Effects of therapy
in oropharyngeal dysphagia by speech and language therapists: a
systematic review. Dysphagia. (2010) 25:40–65. doi: 10.1007/s00455-
009-9239-7
90. Dafsari HS, Silverdale M, Strack M, Rizos A, Ashkan K, Mahlstedt
P, et al. Nonmotor symptoms evolution during 24 months of bilateral
subthalamic stimulation in Parkinson’s disease.MovDisord. (2018) 33:421–30.
doi: 10.1002/mds.27283
91. Bronner G. Sexual problems in Parkinson’s disease: the multidimensional
nature of the problem and of the intervention. J Neurol Sci. (2011) 310:139–43.
doi: 10.1016/j.jns.2011.05.050
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Mendoza-Velásquez, Flores-Vázquez, Barrón-Velázquez, Sosa-
Ortiz, Illigens and Siepmann. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 363
